Dynavax Technologies | Umsatzkosten



Cost Of Sales Veränderung Datum
AbbVie USD 4.35B 344M 2025-06
Adma Biologics USD 54.22M 5.96M 2024-12
Amgen USD 2.6B 507M 2025-03
AstraZeneca USD 2.47B 232M 2025-06
Biogen USD 605M 24.3M 2025-06
BioMarin Pharmaceutical USD 154.94M 3.38M 2025-06
Bristol-Myers Squibb USD 3.37B 339M 2025-06
Dynavax Technologies USD 14.04M 13.5M 2025-06
Gilead Sciences USD 1.5B 39M 2025-06
Glaxosmithkline GBP 2.52B 199M 2024-12
Merck USD 2.82B 53M 2025-06
Neurocrine Biosciences USD 11.3M 2.1M 2025-06
Novartis USD 3.32B 95M 2025-06
Pfizer USD 4.99B 2.4B 2025-06
Regeneron Pharmaceuticals USD 530.2M 264.7M 2025-06
Roche Holding CHF 4.13B 393.5M 2024-12
Sarepta Therapeutics USD 153.22M 15.66M 2025-06
TG Therapeutics USD 18.94M 3.4M 2025-06
Vertex Pharmaceuticals USD 407.5M 44.5M 2025-06


Dynavax Technologies Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Aug 2025.